Fig. 3: ADCT-701 induces robust anti-tumor responses in DLK1+ ACC tumors. | Nature Communications

Fig. 3: ADCT-701 induces robust anti-tumor responses in DLK1+ ACC tumors.

From: Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma

Fig. 3

A CU-ACC1 and H295R xenograft tumor growth curves after treatment with saline (CU-ACC1: n = 3; H295R: n = 4), B12-PL1601 (CU-ACC1: n = 3; H295R: n = 4), or ADCT-701 (CU-ACC1: n = 3; H295R: n = 3) (1 mg/kg) (initial tumor size reached an average of 100–150 mm3). Additional doses of ADCT-701 indicated by arrows. Error bars represent mean values ± S.E.M. B ACC PDXs 164165, 592788, and POBNCI_ACC004 tumor growth curves after treatment with saline (164165: n = 8; 592788: n = 7; POBNCI_ACC004: n = 5), B12-PL1601 (164165: n = 7; 592788: n = 7; POBNCI_ACC004: n = 5) or ADCT-701 (164165: n = 8; 592788: n = 6; POBNCI_ACC004: n = 5) (1 mg/kg) (initial tumor size reached an average of 100–200 mm3). Each line shown represents an individual mouse within a given experiment. The X symbol indicates the administration of ADCT-701 re-dosing. Arrow indicates unexpected death of 1 POBNCI_ACC004 tumor-bearing mouse prior to endpoint. DLK1 immunohistochemistry with H-scores shown above each individual xenograft or PDX tumor. PR partial response, CR complete response. Scale bars represent 200 μm. Source data are provided as a Source Data file.

Back to article page